158 related articles for article (PubMed ID: 36210555)
1. Venous thromboembolism and risk stratification in hematological malignancies.
Sanfilippo KM
Thromb Res; 2022 May; 213 Suppl 1():S16-S21. PubMed ID: 36210555
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism in the hematologic malignancies.
Falanga A; Marchetti M; Russo L
Curr Opin Oncol; 2012 Nov; 24(6):702-10. PubMed ID: 23014188
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.
Wun T; White RH
Thromb Res; 2010 Apr; 125 Suppl 2():S96-102. PubMed ID: 20434017
[TBL] [Abstract][Full Text] [Related]
4. Assessing the risk of venous thromboembolism in multiple myeloma.
Sanfilippo KM
Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism in the hematologic malignancies.
Falanga A; Marchetti M
J Clin Oncol; 2009 Oct; 27(29):4848-57. PubMed ID: 19752334
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for venous thromboembolism in hospitalized patients with hematological malignancy: an analysis of the National Inpatient Sample, 2011-2015.
Bakalov V; Tang A; Yellala A; Kaplan R; Lister J; Sadashiv S
Leuk Lymphoma; 2020 Feb; 61(2):370-376. PubMed ID: 31545108
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism incidence in hematologic malignancies.
Kekre N; Connors JM
Blood Rev; 2019 Jan; 33():24-32. PubMed ID: 30262170
[TBL] [Abstract][Full Text] [Related]
8. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies.
Sorigue M; Cañamero E; Siguenza P; Nomdedeu M; López-Núñez JJ
Leuk Lymphoma; 2020 Jun; 61(6):1277-1291. PubMed ID: 31960713
[TBL] [Abstract][Full Text] [Related]
9. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis in Lymphoma Patients and in Myeloma Patients.
Yokoyama K
Keio J Med; 2015; 64(3):37-43. PubMed ID: 26212069
[TBL] [Abstract][Full Text] [Related]
11. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Dima D; Li A; Granat LM; Dhillon P; Chamseddine F; Yalamanchali A; Mirzai S; Wei W; Samaras CJ; Valent J; Anwer F; Khouri J
Br J Haematol; 2023 Apr; 201(2):280-284. PubMed ID: 36604838
[TBL] [Abstract][Full Text] [Related]
12. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
14. [Prophylaxis and treatment of hematological malignancy-associated thrombosis].
Ikezoe T
Rinsho Ketsueki; 2023; 64(9):1137-1143. PubMed ID: 37899193
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort.
Gade IL; Brækkan S; Næss IA; Hansen JB; Rosendaal F; Cannegieter S; Overvad K; Jensvoll H; Hammerstrøm J; Gran OV; Tjønneland A; Kristensen SR; Severinsen MT
Thromb Res; 2017 Oct; 158():157-160. PubMed ID: 28926801
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival.
Ku GH; White RH; Chew HK; Harvey DJ; Zhou H; Wun T
Blood; 2009 Apr; 113(17):3911-7. PubMed ID: 19088376
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment of venous thromboembolism in hematological cancer patients: a review.
Chan TS; Hwang YY; Tse E
Expert Rev Hematol; 2020 May; 13(5):471-480. PubMed ID: 32249620
[No Abstract] [Full Text] [Related]
18. Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.
Baker HA; Brown AR; Mahnken JD; Shireman TI; Webb CE; Lipe BC
Cancer Med; 2019 Jan; 8(1):455-462. PubMed ID: 30585435
[TBL] [Abstract][Full Text] [Related]
19. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
[TBL] [Abstract][Full Text] [Related]
20. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.
Covut F; Sanfilippo KM
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):363-367. PubMed ID: 36485142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
